Le Lézard
Classified in: Health
Subject: PDT

Bionaze Probiotic awarded Federal Trademark


BOCA RATON, Fla., Aug. 23, 2019 /PRNewswire/ -- Specifically designed for ear, nose, and throat (ENT) care, the Bionaze probiotic supplement was awarded a U.S. Federal Trademark #5836379.   "We are very pleased that to receive the trademark for Bionaze as this will further enhance the value of our marketing strategy for this amazing new probiotic formula" says Bionaze's CEO Steve Williams.

The Bionaze product next to it's box. Bionaze is an all natural probiotic consisting of two clinically studied and patented probiotic bacteria strains. Studies have shown them to be effective in reducing the negative effects of chronic ear, nose, throat and sinus issues.

Bionaze is formulated with BLIS K12 and BL-04, both cutting edge probiotic strains clinically proven to prevent and reduce bacteria from taking hold.  Bionaze acts as a probiotic force field targeting chronic ENT and mouth issues thus preventing harmful bacterial growth. 

BLIS K12 is a relatively new probiotic strain with proven potential. Its main health benefit is getting rid of streptococcus pyogene - a harmful bacteria that causes tonsilitis, scarlet fever, and similar infections. BLIS K12 is also the strain of good bacteria responsible for infants "baby breath" and provides users long lasting breath benefit.

Bionaze works by attaching to your oral cavity and crowding out the bad bacteria inside. That's why it's ideal for getting rid of halitosis, gum disease or dry throat and using prior to, during and after being exposed to large groups of people such as while traveling or at sporting events.

In Milan, a study has confirmed the effectiveness of Bionaze's BLIS K12 in preventing streptococcal pharyngotonsilitis in children. The American Society for Microbiology also found that it helps prevent severe candidiasis.

Meanwhile, several studies have proven that the BL-04 contained in Bionaze is very effective in boosting immunity and preventing Strep Throat. In Australia, a trial was conducted to determine what probiotic strain best promotes immune functions. Participants who were given BL-04 have shown a 27% lower incidence of upper respiratory infections after 5 months. 

Recent clinical evidence shows that it also helps alleviate rhinovirus and hay fever in both adults and children. 

For those struggling with nasal allergies, this one two punch blend of probiotic strains each has proven to improve sinus health too. It does this by maintaining a healthy balance of bacteria in the upper respiratory tract. This, in turn, improves our body's tolerance to allergens.

Bionaze helps improve breathing, eliminates post-nasal drip and helps reduce phlegm by promoting proper drainage.

Williams started further,  "We know that for probiotic bacteria must reach your body alive. The two particular strains contained in Bionaze need time to attach in order to propagate in your oral cavities. Bionaze is formulated to taste great so we are very confident in the overall market acceptability and prospects for long term use."

"The slow dissolving lozenge exposes the bacteria to your oral surfaces for an extended period. This lets them to more effectively colonize your mouth and upper respiratory area. The longer it stays there, the faster you will feel its effects."

For more information about Bionaze visit www.Bionaze.com. Contact [email protected] or call 800.931.1822.

SOURCE Bionaze


These press releases may also interest you

at 06:00
The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in...

at 06:00
65,000 Ontario hospital workers represented by the Ontario Council of Hospital Unions-CUPE (OCHU-CUPE) and SEIU Healthcare will see a 6% wage increase (3% wage increases in each of the next two years), improvements to health and dental benefits,...

at 05:29
SmartCella Holding AB today announces that Dr Ricardo Baptista has been appointed Chief Technology Officer (CTO) and Head of Procella. Ricardo is an experienced Biochemical Engineer with almost 20-years of global experience in the medical...

at 05:15
Every year in Quebec, more than 2,000 young people leave the care of the Director of Youth Protection (DYP) as they approach the age of majority. For youth under the care of the DYP, turning 18 means having to become independent quickly, with little...

at 03:00
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...



News published on and distributed by: